Neoral® rescue therapy in transplant patients with intolerance to tacrolimus

Background. The calcineurin inhibitors, cyclosporine and tacrolimus, are the mainstay of current immunosuppressive regimens for the prevention of acute rejection in organ transplantation. The choice of the individual agent used often depends on the preference of the Transplant Center and patient type. Adverse effects associated with tacrolimus may impact its clinical utility in many patients. This study characterizes the clinical outcomes of transplant recipients who experienced adverse effects from tacrolimus and were converted to cyclosporine‐microemulsion‐based (Neoral® [cyclosporine, USP] MODIFIED) therapy.

[1]  T. Yagisawa,et al.  Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience. , 2000, Transplantation proceedings.

[2]  P. Belitsky,et al.  Neoral use in the renal transplant recipient. , 2000, Transplantation proceedings.

[3]  H. Valantine.  Neoral use in the cardiac transplant recipient. , 2000, Transplantation proceedings.

[4]  G. Levy.  Neoral use in the liver transplant recipient. , 2000, Transplantation proceedings.

[5]  R. Higgins,et al.  Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. , 2000, Transplantation.

[6]  E. Kanal,et al.  Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. , 2000, Transplantation.

[7]  T. Fishbein,et al.  Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients , 2000, Transplant international : official journal of the European Society for Organ Transplantation.

[8]  D. Leehey,et al.  Improved graft survival after renal transplantation in the United States, 1988 to 1996. , 2000, The New England journal of medicine.

[9]  B. Kahan.  Cyclosporine: a revolution in transplantation. , 1999, Transplantation proceedings.

[10]  P. Keown,et al.  Cyclosporine: the principal immunosuppressant for renal transplantation. , 1998, Transplantation proceedings.

[11]  C. Margarit,et al.  Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. , 1998, Transplantation proceedings.

[12]  M. Schwartz,et al.  Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. , 1994, Transplantation proceedings.

[13]  S. Silbiger,et al.  THE IMPACT OF GENDER ON RENAL TRANSPLANTATION , 1994, Transplantation.

[14]  M. Schwartz,et al.  Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. , 1994, Transplantation.

[15]  M. Schwartz,et al.  Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. , 1994, Transplantation.

[16]  W. Bechstein,et al.  Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. , 1994, Transplantation.

[17]  D. V. van Thiel,et al.  Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. , 1994, Journal of hepatology.

[18]  B. Kahan.  Drug therapy: cyclosporine , 1989 .

[19]  D. S. Gordon,et al.  Cyclosporine , 1986, Transplantation proceedings.

[20]  Hristopher,et al.  IMPROVED GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION IN THE UNITED STATES , 1988 TO 1996 , 2022 .